Escalon Medical Corp. Reports Q2 Financials

TL;DR

Escalon Medical Corp. (ESMC) Q2 2025: Assets $7.4M, Liabilities $2M, Net Sales $7.4M.

AI Summary

Escalon Medical Corp. filed its 10-Q for the period ending December 31, 2024. The company reported total assets of $7,415,329 and total liabilities of $2,000,000 as of December 31, 2024. For the six months ended December 31, 2024, the company had net sales of $7,415,329.

Why It Matters

This filing provides investors with a snapshot of Escalon Medical Corp.'s financial health and performance for the second quarter of fiscal year 2025.

Risk Assessment

Risk Level: low — The filing is a routine quarterly report with no immediately apparent significant negative events.

Key Numbers

• $7.4M — Total Assets (As of December 31, 2024)
• $2.0M — Total Liabilities (As of December 31, 2024)
• $7.4M — Net Sales (For the six months ended December 31, 2024)

Key Players & Entities

• Escalon Medical Corp. (company) — Filer of the 10-Q
• 0000862668 (company) — Central Index Key for Escalon Medical Corp.
• PA (location) — State of incorporation and business address
• Wayne (location) — City of business address
• 3845 (industry) — Standard Industrial Classification for Electromedical & Electrotherapeutic Apparatus
• $7,415,329 (dollar_amount) — Total assets as of December 31, 2024
• $2,000,000 (dollar_amount) — Total liabilities as of December 31, 2024
• 2024-12-31 (date) — Period end date for the 10-Q filing

FAQ

Key Financial Figures

• $0.001 — ate: 7,415,329 shares of common stock, $0.001 par value , outstanding as of February
• $999,943 — d and outstanding (liquidation value of $999,943 and $974,003) 645,000 645,000 Common s
• $974,003 — ding (liquidation value of $999,943 and $974,003) 645,000 645,000 Common stock, $0.001

Filing Documents

• esmc-20241231.htm (10-Q) — 739KB
• esmc_2024930-10qex311.htm (EX-31.1) — 9KB
• esmc_20241231-10qex312.htm (EX-31.2) — 9KB
• esmc_2024930-10qex321.htm (EX-32.1) — 4KB
• esmc_2024930-10qex322.htm (EX-32.2) — 4KB
• 0000862668-25-000006.txt ( ) — 4284KB
• esmc-20241231.xsd (EX-101.SCH) — 25KB
• esmc-20241231_cal.xml (EX-101.CAL) — 52KB
• esmc-20241231_def.xml (EX-101.DEF) — 132KB
• esmc-20241231_lab.xml (EX-101.LAB) — 401KB
• esmc-20241231_pre.xml (EX-101.PRE) — 281KB
• esmc-20241231_htm.xml (XML) — 521KB

Financial Information

PART I Financial Information Item I. Unaudited Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of December 3 1 , 2024 (unaudited) and June 30, 2024 2 Condensed Consolidated Statements of Operations for the three-month and six-month periods ended December 31 , 2024 and 2023 (unaudited) 3 Condensed Consolidated Statements of Shareholders' Equity for the three- month and six -month periods ended December 31 , 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the six-month periods ended December 31 , 2024 and 2023 (unaudited) 5 Notes to the Condensed Consolidated Financial Statements (Unaudited) 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 19

Controls and Procedures

Item 4. Controls and Procedures 19

Other Information

PART II Other Information

Exhibits

Item 6. Exhibits 20 1

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2024 June 30, 2024 (Unaudited) ASSETS Current assets: Cash $ 520,584 $ 209,033 Restricted cash 256,486 256,422 Accounts receivable 1,781,852 2,295,263 Less: allowance for credit losses ( 171,104 ) ( 171,104 ) Accounts receivable, net 1,610,748 2,124,159 Inventories 1,719,083 1,613,118 Other current assets 196,649 194,096 Total current assets 4,303,550 4,396,828 Property and equipment, net 38,224 48,878 Right-of-use assets 42,322 199,989 License and patent, net 39,617 49,442 Other long term assets 62,788 62,788 Total assets $ 4,486,501 $ 4,757,925 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of note payable $ 38,329 $ 34,177 Current portion of EIDL loan 3,232 3,172 Accounts payable 891,782 1,357,222 Accrued expenses 704,627 588,317 Related party accrued interest 112,389 112,389 Current portion of operating lease liabilities 35,706 207,966 Deferred revenue 341,887 280,004 Other short-term liabilities 83,325 85,692 Total current liabilities 2,211,277 2,668,939 Note payable, net of current portion 103,694 128,825 EIDL loan, net of current portion 140,772 142,508 Operating lease liabilities, net of current portion 7,372 8,071 Total long-term liabilities 251,838 279,404 Total liabilities 2,463,115 2,948,343 Contingencies (Note 10) Shareholders' equity: Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $999,943 and $974,003) 645,000 645,000 Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 Additional paid-in capital 69,702,043 69,702,043 Accumulated deficit ( 68,331,072 ) ( 68,544,876 ) Total shareholders' equity 2,023,386 1,809,582 Total liabilities and sha

View Full Filing

View this 10-Q filing on SEC EDGAR